Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR5A | P47898 | 5/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | AHR | P35869 | 1/20 | 0.45 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | HK1 | P19367 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | GALK1 | P51570 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2041999 | 0.85 | — | — | |
| SCHEMBL30668800 | 0.85 | — | — | |
| SCHEMBL1828551 | 0.85 | — | — | |
| Ammonia Solution, Strong SCHEMBL7208186 | 0.82 | — | — | |
| SCHEMBL3522841 | 0.81 | CHEK1 (0.49) | HTR5AALOX15HSD17B10GAANPSR1 | |
| SCHEMBL29532858 | 0.81 | CHEK1 (0.49) | HTR5AALOX15HSD17B10GAANPSR1 | |
| SCHEMBL11441092 | 0.79 | HTR5A (0.55) | HTR5AALOX15HSD17B10GAANPSR1 | |
| SCHEMBL19156605 | 0.78 | AHR (0.47) | HTR5AALOX15HSD17B10GAANPSR1 | |
| SCHEMBL19350808 | 0.78 | KDM4E (0.54) | HTR5AALOX15HSD17B10GAANPSR1 | |
| Naphthalene SCHEMBL11345152 | 0.78 | ALOX15 (0.64) | HTR5AALOX15HSD17B10GAANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12152216-B2 | Benzazepine compounds as antioxidants for lubricant compositions | The Lubrizol Corp tion (US) | 2024-11-26 | — | — | US | disclosed |
| US-20240052256-A1 | BENZAZEPINE COMPOUNDS AS ANTIOXIDANTS FOR LUBRICANT COMPOSITIONS | THE LUBRIZOL CORPORATION | 2024-02-15 | — | — | US | disclosed |
| US-20230094176-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENT AB (SE) | 2023-03-30 | — | — | US | disclosed |
| EP-3250035-B1 | COMPOUNDS AND THEIR USE AS BACE1 INHIBITORS | ALLGENESIS BIOTHERAPEUTICS INC (TW) | 2023-01-25 | — | — | EP | disclosed |
| WO-2021154976-A1 | METHODS OF TREATING BRAIN CANCER WITH PANOBINOSTAT | SECURA BIO, INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| US-20210060014-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENTIFIC AB (SE) | 2021-03-04 | — | — | US | disclosed |
| EP-3470413-A2 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES | Ambrx, Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| EP-2139850-B1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC (CA) | 2018-09-12 | — | — | EP | disclosed |
| US-20180201604-A1 | COMPOUNDS AND THEIR USE AS BACE1 INHIBITORS | ALLGENESIS BIOTHERAPEUTICS, INC. (TW) | 2018-07-19 | — | — | US | disclosed |
| EP-3250035-A1 | COMPOUNDS AND THEIR USE AS BACE1 INHIBITORS | Allgenesis Biotherapeutics Inc. (TW) | 2017-12-06 | — | — | EP | disclosed |
| US-20020198191-A1 | Medicine for inducing temporary delay of urination or treatment of disorders of diabetes insipidus, nocturnal enuresis, nocturia, urinary incontinence, or bleeding and coagulation disorders | WYETH (US) | 2002-12-26 | — | — | US | disclosed |
| US-20020177593-A1 | Agents and crystals for improving excretory potency of urinary bladder | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2002-11-28 | — | — | US | disclosed |
| WO-2002083685-A1 | CYCLOHEXYLPHENYL VASOPRESSIN AGONISTS | WYETH (US) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002022577-A2 | HYDROXAMATE DERIVATIVES USEFUL AS DEACETYLASE INHIBITORS | NOVARTIS AG (CH) | 2002-03-21 | — | — | WO | disclosed |
| EP-1118322-A1 | DRUGS FOR IMPROVING VESICAL EXCRETORY STRENGTH | Takeda Chemical Industries, Ltd. (JP) | 2001-07-25 | — | — | EP | disclosed |
| EP-0975624-A1 | THERMOGENIC COMPOSITION AND BENZAZEPINE THERMOGENICS | Takeda Chemical Industries, Ltd. (JP) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998046590-A1 | THERMOGENIC COMPOSITION AND BENZAZEPINE THERMOGENICS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-10-22 | — | — | WO | disclosed |
| WO-1996022282-A1 | TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS | AMERICAN CYANAMID COMPANY (US) | 1996-07-25 | — | — | WO | disclosed |
| US-5527800-A | A 4H-PYRROLO(3,2,1-IJ)QUINOLIN-8-YL DERIVATIVE ADMINISTERED FOR THERAPY OR PROPHYLAXIS OF SENILE DEMENTIA | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-06-18 | — | — | US | disclosed |
| EP-0607864-A2 | Tricyclic condensed heterocyclic compounds for the treatment of senile dementic | Takeda Chemical Industries, Ltd. (JP) | 1994-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180201604-A1 | COMPOUNDS AND THEIR USE AS BACE1 INHIBITORS | BACE1, BACE2, APP | HTR5A 777/4885ALOX15 3512/4885HSD17B10 3469/4885 |
| US-20020198191-A1 | Medicine for inducing temporary delay of urination or treatment of disorders of diabetes insipidus, nocturnal enuresis, nocturia, urinary incontinence, or bleeding and coagulation disorders | F2, AVPR2, SHBG | HTR5A 726/4885ALOX15 2007/4885HSD17B10 1691/4885 |
| US-20020177593-A1 | Agents and crystals for improving excretory potency of urinary bladder | ACHE, BPHL, BCHE | HTR5A 3109/4885ALOX15 3233/4885HSD17B10 3205/4885 |
| US-20210060014-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC2 | HTR5A 3894/4885ALOX15 1088/4885HSD17B10 303/4885 |
| US-20230094176-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC2, HDAC1 | HTR5A 3789/4885ALOX15 1305/4885HSD17B10 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.